

## GNAO1 Haploinsufficiency: The Milder End of the GNAO1 Phenotypic Spectrum

*GNAO1* variants are typically associated with severe, early-onset movement disorders (MDs) with life-threatening and drug-resistant paroxysmal exacerbations, neurodevelopmental disorders, and epilepsy. Recently, the phenotypic spectrum has broadened to include milder phenotypes with late-onset dystonia, minor cognitive impairment, and other neurological signs, including parkinsonism and myoclonus. *GNAO1* haploinsufficiency has been evoked as a putative mechanism underlying milder clinical presentations.<sup>1,2</sup> To date, however, the functional consequences of this class of variants have not yet been evaluated.

We report on an 8-year-old boy with subtle neurological signs, including generalized tonic-clonic seizures during fever, mild language impairment, dystonic postures of lower limbs during walking, and occasional tongue dyskinetic movements (see Data S1 for more details and Video 1). A next generation sequencing-based epilepsy panel revealed a de novo NM\_020988.3:c.163\_164del variant in *GNAO1*. No additional candidate variants were identified. Reverse transcription polymerase chain reaction showed an approximately 50% decrease in the expression of the endogenous *GNAO1* gene in cells from the affected child compared with cells from the unaffected father (Figs. 1A and S2), suggesting nonsense-mediated mRNA decay (NMD). If translated, the c.163\_164delAT allele was predicted to generate a truncated protein (p.Ile55Hisfs\*3). As expected, Western blotting performed in transiently transfected HEK293T cells revealed the lack of the truncated form of G $\alpha$  (Fig. 1B), which was not restored by MG132 or



**VIDEO. 1.** The patient at the age of 7 years while walking, running, standing, and jumping on one foot. [Color figure can be viewed at [wileyonlinelibrary.com](https://onlinelibrary.wiley.com/doi/10.1002/mds.29585)] Video content can be viewed at <https://onlinelibrary.wiley.com/doi/10.1002/mds.29585>

bafilomycin treatments, inhibitors of the ubiquitin/proteasome and autophagy pathways, respectively. These findings demonstrate that the c.163\_164delAT transcript undergoes NMD, leading to *GNAO1* haploinsufficiency.

Genotype/phenotype correlations in *GNAO1* encephalopathy are still far from being elucidated. Recent studies suggest that pathogenic variants have a loss-of-function effect on G $\alpha$ -mediated signaling,<sup>3-7</sup> but the consequences on G-beta-gamma subunit (G $\beta\gamma$ ) signaling that regulates cyclic adenosine monophosphate production remain unclear. Emerging data show that haploinsufficiency is associated with milder clinical features and later onset than missense changes underlying developmental and epileptic encephalopathy type 17 (Mendelian inheritance in man [MIM]#615473) or neurodevelopmental disorder with involuntary movements (MIM#617493). This finding has important implications. First, given the different phenotypic output, variants associated with the canonical form of *GNAO1* encephalopathy cannot have a simple loss-of-function effect; rather, they behave as dominant-negative alleles or alter G $\alpha$ /G $\beta\gamma$  association, as recently shown for a subset of changes.<sup>3-7</sup> Second, the phenotype associated with *GNAO1* haploinsufficiency is likely attributed to increased levels of free G $\beta\gamma$  in the brain, which, in turn, could lead to increased receptor-independent G $\beta\gamma$  signaling in neurons. Finally, the association of *GNAO1* haploinsufficiency with a subtle but distinctive phenotype may help to design a proper gene therapy strategy. Allele-specific silencing by antisense oligonucleotides or short-interfering RNAs is unlikely to be a reasonable approach because 50% of the gene dosage is not neutral and single nucleotide substitutions hardly confer a complete discrimination for allele-specific targeting. In contrast, AAV-mediated gene supplementation coupled with silencing of the mutant allele is expected to effectively alleviate the disease phenotype.

Our findings also indicate that *GNAO1* variants may be more frequent than previously estimated and encourage testing for this gene in patients with mild neurological signs

© 2023 The Authors. *Movement Disorders* published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial-NoDerivs](https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.


\*Correspondence to: Dr. Serena Galosi, Unit of Child Neurology and Psychiatry, Department of Human Neuroscience, Sapienza University of Rome, Via dei Sabelli 108, 00185, Rome, Italy; E-mail: [serena.galosi@uniroma1.it](mailto:serena.galosi@uniroma1.it)

**Relevant conflicts of interest/financial disclosures:** Nothing to report.

**Funding agencies:** This work was partially supported by the Istituto Superiore di Sanità (Ricerca Indipendente 2020-2022\_ISS20-0ab01a06bd2a to S.M.). M.R. was recipient of a research fellowship from the Italian *GNAO1* patients association "Famiglie *GNAO1*". R.G. coordinates the DECODEE project of the Tuscany Region.

**Received:** 13 July 2023; **Revised:** 28 July 2023; **Accepted:** 21 July 2023

Published online 26 August 2023 in Wiley Online Library ([wileyonlinelibrary.com](https://onlinelibrary.wiley.com)). DOI: 10.1002/mds.29585



**FIG. 1.** The c.163\_164delAT variant leads to *GNAO1* haploinsufficiency. (A) Reverse transcription polymerase chain reaction shows a significant decrease in endogenous *GNAO1* mRNA levels in cells from the affected child compared with cells from the unaffected father. Values are normalized to the expression of WT *GNAO1*. GAPDH was used as an internal control. Bars indicate mean values  $\pm$  standard deviation of three independent experiments, each performed in triplicate. The fold change was calculated using the  $\Delta\Delta\text{CT}$  formula. Results were analyzed using a two-tailed unpaired *t* test with Bonferroni correction ( $P < 0.0001$ ). (B) Western blot analysis shows the lack of the mutant protein, which is confirmed following treatment with MG132 (proteasome inhibitor) or bafilomycin (autophagy inhibitor), further supporting that the c.163\_164delAT variant causes mRNA decay. Equal amounts of cell lysates were resolved by 4% to 20% polyacrylamide gradient gel electrophoresis. Membranes were probed with a mouse monoclonal anti-Xpress antibody and reprobed with a mouse monoclonal anti-GAPDH antibody for protein normalization. The blot is representative of three independent experiments.  $\Delta\Delta\text{CT}$ , delta delta CT; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; WT, wild type.

featuring epilepsy and/or MDs without a definite diagnosis. The progression into more severe phenotypes, and possible neurological deterioration induced by triggering events, typical for this condition, deserve a careful and prolonged clinical follow-up. ●

### Ethical Compliance Statement

Written informed consent for offline and online video distribution of the video material was obtained from parents and is available upon request. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this work is consistent with those guidelines. The authors confirm that the approval of an institutional review board was not required for this work. ●

**Acknowledgments:** We thank the patient and his family for participating in this study.

### Data Availability Statement

The data that support the findings of this study are available on request from the corresponding author.

Serena Galosi, MD, PhD,<sup>1\*</sup> Maria Novelli, MD,<sup>1</sup> Martina Di Rocco, PhD,<sup>1,2</sup> Elisabetta Flex, PhD,<sup>2</sup> Elena Messina, PhD,<sup>3</sup> Luca Pollini, MD,<sup>1</sup> Elena Parrini, PhD,<sup>4</sup> Francesco Pisani, MD,<sup>1</sup> Renzo Guerrini, MD, FRCP,<sup>4</sup> Vincenzo Leuzzi, MD,<sup>1</sup> and Simone Martinelli, PhD<sup>2</sup>

<sup>1</sup>Department of Human Neuroscience, "Sapienza" University of Rome, Rome, Italy, <sup>2</sup>Department of Oncology and Molecular

Medicine, Istituto Superiore di Sanità, Rome, Italy, <sup>3</sup>Genetics and Rare Diseases Research Division, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy, and <sup>4</sup>Neuroscience Department, Children's Hospital Meyer IRCCS, Florence, Italy

## References

- Krenn M, Sommer R, Sycha T, Zech M. GNAO1 haploinsufficiency associated with a mild delayed-onset dystonia phenotype. *Mov Disord* 2022;37:2464–2466.
- Wirth T, Garone G, Kurian MA, et al. Highlighting the dystonic phenotype related to GNAO1. *Mov Disord* 2022;37:1547–1554.
- Muntean BS, Masuho I, Dao M, et al. Gαo is a major determinant of cAMP signaling in the pathophysiology of movement disorders. *Cell Rep* 2021;34:108718.
- Wang D, Dao M, Muntean BS, et al. Genetic modeling of GNAO1 disorder delineates mechanisms of Gαo dysfunction. *Hum Mol Genet* 2022;31:510–522.
- Di Rocco M, Galosi S, Lanza E, et al. *Caenorhabditis elegans* provides an efficient drug screening platform for GNAO1-related disorders and highlights the potential role of caffeine in controlling dyskinesia. *Hum Mol Genet* 2022;31:929–941.
- Di Rocco M, Galosi S, Follo FC, et al. Phenotypic assessment of pathogenic variants in GNAO1 and response to caffeine in *C. elegans* models of the disease. *Genes (Basel)* 2023;14:319.
- Larasati YA, Savitsky M, Koval A, et al. Restoration of the GTPase activity and cellular interactions of Gαo mutants by Zn<sup>2+</sup> in GNAO1 encephalopathy models. *Sci Adv* 2022;8:eabn9350.

## Supporting Data

Additional Supporting Information may be found in the online version of this article at the publisher's web-site.